Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD

Pulmonary Disease, Chronic Obstructive Clinical Trial

Official title:

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00749411
• Other study ID #: DB1111581
• Status: Completed
• Phase: Phase 2
• Start date: November 13, 2008
• Est. completion date: February 12, 2009

Study information

• Verified date: August 2020
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is the evaluate the safety and tolerability of repeat dosing of the combination of inhaled GSK233705 and GW642444 administered once-daily in subjects with COPD.

Other known NCT identifiers

• NCT00843206

Recruitment information / eligibility

• Status: Completed
• Enrollment: 61
• Est. completion date: February 12, 2009
• Est. primary completion date: February 12, 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• male and females 40 to 80 years of age (inclusive)

• COPD diagnosis

• Current or previous smokers with a cigarette smoking history of at least 10 pack-

• Post-albuterol FEV1/FVC of 0.70 or less

• Post-albuterol FEV1 of 35% to 80% (inclusive)

Exclusion Criteria:

• Pregnant or lactating females

• current diagnosis of asthma

• respiratory disorders other than COPD

• clinically significant cardiovascular, neurological, psychiatric, renal, immunological, endocrine, or hematological abnormalities that are uncontrolled

• clinically significant sleep apnea

• previous lung resection surgery

• clinically significant abnormalities confirmed by chest x-ray that are not related to COPD

• hospitalization for COPD within 3 months of screening

• use of antibiotics for lower respiratory tract infection within 6 months of screening

• abnormal and clinically significant 12-lead ECG findings

• current malignancy in remission for less that 5 years

• medical conditions that would contraindicate the use of anticholinergics

• positive hepatitis B or C test

• history of alcohol or drug abuse

• unable to withhold albuterol for 6 or more hours

• use of long term oxygen therapy

• conditions that would limit the validity of informed consent

• use of GW642444 or GSK233705 in previous studies

• use of an investigation drug with 30 days of screening

• use of inhaled corticosteroids (ICS) at a dose greater than 1000mcg of fluticasone propionate or equivalent

• hypersensitivity to beta-agonists

• concurrent use of long-acting beta-agonists (LABA) or long-acting muscaring antagonists, LABA/ICS combination products, cytochrome p450 inhibitors, oral or depot corticosteroids, theophyllines, oral beta agonists, oral leukotrine modulators, inhaled short acting anticholinergics.

Related Conditions & MeSH terms

• Lung Diseases
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• Placebo
matching placebo
• GSK233705/GW642444
The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.

Locations

Country	Name	City	State
United States	GSK Investigational Site	Biddeford	Maine
United States	GSK Investigational Site	Erie	Pennsylvania
United States	GSK Investigational Site	Greenville	South Carolina
United States	GSK Investigational Site	Johnson City	Tennessee
United States	GSK Investigational Site	Medford	Oregon
United States	GSK Investigational Site	Mobile	Alabama
United States	GSK Investigational Site	Saint Louis	Missouri
United States	GSK Investigational Site	San Antonio	Texas
United States	GSK Investigational Site	Spartanburg	South Carolina
United States	GSK Investigational Site	Spokane	Washington
United States	GSK Investigational Site	Summit	New Jersey
United States	GSK Investigational Site	Wheat Ridge	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United States, 

References & Publications (1)

GSK has submitted manuscripts of these study results to peer-reviewed scientific journals which were not accepted for publication. GSK is providing the attached study results summary with a conclusion.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Weighted Mean Pulse Rate Over (0-4 Hours) at Day 28.	Baseline was the most recent result taken on or before pre-dose (Day 1). The analysis was performed using a Repeated Measures Model. This model used all available weighted mean pulse rate values recorded. Change from Baseline was calculated as (Change from Baseline = Assessment value - Baseline value).	Baseline (Pre-dose, Day 1) and Day 28
Secondary	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.	On-treatment; from treatment start until one day after treatment stop (Up to Day 29)

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.